SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost
1 references·1 citing·10 second hop
The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost (2019)The Landscape of Cellular and Gene Therap…Advanced therapy medicinal products: current and future perspectives (2016)Advanced therapy medicinal pr…Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Potential approaches for the …Assessing the economic challenges posed by orphan drugs (2007)The High Cost of Cancer Drugs and What We Can Do About It (2012)Economic burden of cancer across the European Union: a population-based cost analysis (2013)Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities (2017)Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe (2018)Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy (2019)The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 (2017)Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3] (2018)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)
this work references cited by second hop

References

  • 2016Advanced therapy medicinal products: current and future perspectives171 cited

Cited by

  • 2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications75 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work